Expert Interview
A Third Look: Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)
Ticker(s): MRUSInstitution: Vall d'Hebron Institute of Oncology
- Clinician scientist in the Vall d'Hebron Barcelona Hospital Campus and Institute of Oncology.
- Involved with Phase 1 Clinical Trials Unit with a special focus on Head and Neck Cancer.
- Research interests include the development of novel predictive biomarkers for targeted therapies and immunotherapies to expand precision oncology across head and neck and rare cancers.
Roughly how many HNSCC patients do you treat?
Added By: wilson_adminHow are HSNCC patients currently treated?
Added By: wilson_adminWhat is your enthusiasm over MCLA-158 on a scale of 1-10?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
